Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 5/2006

01-05-2006

Abdominal Visceral Lesions in von Hippel-Lindau Disease: Incidence and Clinical Behavior of Pancreatic and Adrenal Lesions at a Single Center

Authors: Keith A. Delman, MD, Suzanne E. Shapiro, MS, Eric W. Jonasch, MD, Jeffrey E. Lee, MD, Steven A. Curley, MD, Douglas B. Evans, MD, Nancy D. Perrier, MD

Published in: World Journal of Surgery | Issue 5/2006

Login to get access

Abstract

Introduction

Von Hippel-Lindau disease (VHL) is a dominantly inherited multi-system syndrome. Although pheochromocytoma is the hallmark endocrine neoplasm, pancreatic lesions occur frequently, and their management can be complex. This report describes 26 patients from a single institution with pancreatic or adrenal lesions (or both) in the background of VHL.

Methods

We reviewed records for all patients treated for adrenal (type 2 VHL) or pancreatic manifestations of VHL at our institution from 1990 to 2004.

Results

Forty patients with VHL were identified from 24 pedigrees; 26 (65%) had adrenal or pancreatic involvement (or both). Seven patients had isolated pheochromocytomas, 16 had isolated pancreatic lesions, and 3 had both. Of the 10 patients with pheochromocytomas, 4 had bilateral adrenal involvement. All but three pheochromocytomas were diagnosed in patients aged 40 years or younger. Of the 19 patients with pancreatic lesions, 8 had cystic lesions, 8 had neuroendocrine tumors, and 3 had both. Of 11 patients with neuroendocrine tumors, 4 had metastases (3 hepatic, 1 nodal). No patient with cystic pancreatic lesions developed carcinoma.

Conclusions

VHL should be familiar to the endocrine surgeon because of the high incidence (65% in our series) of visceral endocrine lesions (pancreas 40%, adrenal gland 18%, both 7%). As seen in other hereditary endocrinopathy syndromes, pheochromocytomas are frequently bilateral; therefore,close follow-up of the contralateral gland in young patients with a unilateral lesion is critical. Cystic lesions of the pancreas may be closely monitored, whereas neuroendocrine tumors should be removed because of the risk of metastasis. Pancreatic pathology is not uncommon in VHL patients with pheochromocytoma and should be sought during the preoperative assessment.
Literature
1.
Shapiro SE, Cote GC, Lee JE, et al. The role of genetics in the surgical management of familial endocrinopathy syndromes. J Am Coll Surg 2003;197:818–831CrossRefPubMed
2.
Curley SA, Lott ST, Luca JW, et al. surgical decision-making affected by clinical and genetic screening of a novel kindred with von Hippel-Lindau disease and pancreatic islet cell tumors. Ann Surg 1998;227:229–235CrossRefPubMed
3.
Jennings CM, Gaines PA. The abdominal manifestation of von Hippel-Lindau disease and a radiological screening protocol for an affected family. Clin Radiol 1988;39:363–367CrossRefPubMed
4.
Hough DM, Stephens DH, Johnson CD, et al. Pancreatic lesions in von Hippel-Lindau disease: prevalence, clinical significance, and CT findings. AJR Am J Roentgenol 1994;162:1091–1094PubMed
5.
Mukhopadhyay B, Sahdev A, Monson JP, et al. Pancreatic lesions in von Hippel-Lindau disease. Clin Endocrinol (Oxf) 2002;57:603–608CrossRef
6.
Hammel PR, Vilgrain V, Terris B, et al. Pancreatic involvement in von Hippel-Lindau disease: the Groupe Francophone D’etude de la Maladie de von Hippel-Lindau. Gastroenterology 2000;119:1087–1095CrossRefPubMed
7.
Libutti SK, Choyke PL, Alexander HR, et al. Clinical and genetic analysis of patients with pancreatic neuroendocrine tumors associated with von Hippel-Lindau disease. Surgery 2000;128:1022–1027CrossRefPubMed
8.
Libutti SK, Choyke PL, Bartlett DL, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery 1998;124:1153–1159CrossRefPubMed
9.
Chen F, Kishida T, Yao M, et al. Germline mutations in the Von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66–75CrossRefPubMed
10.
Crossey PA, Richards FM, Foster K, et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Mol Genet 1994;3:1303–1308PubMed
11.
Lee JE, Curley SA, Gagel RF, et al. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996;120:1064–1071PubMed
12.
Yip L, Lee JE, Shapiro SE, et al. Surgical management of hereditary pheochromocytoma. J Am Coll Surg 2004;198:525–535CrossRefPubMed
13.
Chetty R, Kennedy M, Ezzat S, et al. Pancreatic endocrine pathology in von Hippel-Lindau disease: an expanding spectrum of lesions. Endocr Pathol 2004;15:141–148CrossRefPubMed
Metadata
Title
Abdominal Visceral Lesions in von Hippel-Lindau Disease: Incidence and Clinical Behavior of Pancreatic and Adrenal Lesions at a Single Center
Authors
Keith A. Delman, MD
Suzanne E. Shapiro, MS
Eric W. Jonasch, MD
Jeffrey E. Lee, MD
Steven A. Curley, MD
Douglas B. Evans, MD
Nancy D. Perrier, MD
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
World Journal of Surgery / Issue 5/2006
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-005-0359-4

Other articles of this Issue 5/2006

World Journal of Surgery 5/2006 Go to the issue

OriginalPaper

Preliminary Report: Functional MRI of the Brain May Be the Ideal Tool for Evaluating Neuropsychologic and Sleep Complaints of Patients with Primary Hyperparathyroidism

Erratum

Re: “Insulin-Like Growth Factors (IGF) I and II Utilize Different Calcium Signaling Pathways in a Primary Human Parathyroid Cell Culture Model”. C. Wong et al (DOI: 10.1007/s00268-005-0339-8)

OriginalPaper

Extent of Disease at Presentation and Outcome for Adrenocortical Carcinoma: Have We Made Progress?

OriginalPaper

Does Familial Non-Medullary Thyroid Cancer Adversely Affect Survival?

OriginalPaper

Classical and Follicular Variant of Papillary Thyroid Carcinoma: A Comparative Study on Clinicopathologic Features and Long-term Outcome

Erratum

Sentinel Lymph Node Biopsy May Be Used to Support the Decision to Perform Modified Radical Neck Dissection in Differentiated Thyroid Carcinoma